Verne Mendel holds a unique position in pharmaceutical development, with a solid base to develop product candidates to treat degenerative diseases, including a neurodegenerative group Parkinson’s, Alzheimer’s and Lou Gehrig’s and a metabolic group including diabetes and its cardiac and neurologic complications, which guarantee its future. The company is a leader whose business and scientific value is built on a foundation of exceptional talent and unique mitochondrial disease technology. Its discovery team embodies a culture of innovation and commitment, with a passion for peoples’ health and wellbeing. The Company aligns the hope and promise of treating initiating events in degenerative diseases to attain longer and healthier lives for patients everywhere along with with the interests of investors.